Ginsenoside RG2

1 paper3 findings

PubChem 21599924 ChEBI 77151 MeSH C026474

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Anhui Provincial Department of Education and 3 more

Animals1

Outcomes

Stem cell differentiation

upin mice1

1 study

Ginsenoside RG2 induces stem cell differentiation in mice.
“Ginsenoside Rg2 mitigates brain aging and cognitive decline by inhibiting α-Syn expression and promoting neurogenesis”
Animalsin aging micedentate gyrus
Ginsenoside Rg2 delays brain aging via inhibiting α-synuclein expression and promoting FoxO-Mediated neurogenesis in mice
Journal of ethnopharmacology12 Mar 2026

Latest

1 in 12 months

Journal of Ethnopharmacology15 Mar

Ginsenoside Rg2 delays brain aging via inhibiting α-synuclein expression and promoting FoxO-Mediated neurogenesis in mice

Experiments in miceInterventions

Paper

Ginsenoside RG2

Outcomes

Latest

Ginsenoside Rg2 delays brain aging via inhibiting α-synuclein expression and promoting FoxO-Mediated neurogenesis in mice

Related